Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2004-10-12
2009-06-23
Desai, Rita J (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S316000, C514S319000, C514S331000, C546S223000
Reexamination Certificate
active
07550485
ABSTRACT:
The present invention is directed to substituted N-heterocycle derivatives, compositions containing these derivatives, and methods of their use for the prevention and treatment of conditions ameliorated by monoamine reuptake including, inter alia, vasomotor symptoms (VMS), sexual dysfunction, gastrointestinal and genitourinary disorders, chronic fatigue syndrome, fibromylagia syndrome, nervous system disorders, and combinations thereof, particularly those conditions selected from the group consisting of major depressive disorder, vasomotor symptoms, stress and urge urinary incontinence, fibromyalgia, pain, diabetic neuropathy, and combinations thereof.
REFERENCES:
patent: 3454554 (1969-07-01), Biel et al.
patent: 4221919 (1980-09-01), Grimova et al.
patent: 4229449 (1980-10-01), Melloni et al.
patent: 4310524 (1982-01-01), Wiech et al.
patent: 4535186 (1985-08-01), Husbands et al.
patent: 4826844 (1989-05-01), Husbands et al.
patent: 5502047 (1996-03-01), Kavey
patent: 6703389 (2004-03-01), Wong et al.
patent: 2002/0107249 (2002-08-01), Wong et al.
patent: 2004/0019101 (2004-01-01), Karlstadt et al.
patent: 2004/0143008 (2004-07-01), Deecher et al.
patent: 2004/0152710 (2004-08-01), Deecher et al.
patent: 2004/0180879 (2004-09-01), Deecher et al.
patent: 2556474 (2004-08-01), None
patent: 0 065 757 (1985-01-01), None
patent: 0 208 235 (1990-01-01), None
patent: 0 303 961 (1994-04-01), None
patent: 1 184 372 (2002-03-01), None
patent: 1 266 659 (2002-12-01), None
patent: WO 91/18602 (1991-12-01), None
patent: WO 97/35586 (1997-10-01), None
patent: WO 99/44601 (1999-09-01), None
patent: WO 00/59851 (2000-10-01), None
patent: WO 01/01973 (2001-01-01), None
patent: 02/30405 (2002-04-01), None
patent: WO 02/064543 (2002-08-01), None
patent: WO 02/064543 (2002-08-01), None
patent: 02/079156 (2002-10-01), None
patent: WO 02/078691 (2002-10-01), None
patent: WO 03/037334 (2003-05-01), None
patent: WO 03/053426 (2003-07-01), None
patent: 03/066004 (2003-08-01), None
patent: WO 03/077897 (2003-09-01), None
patent: WO 2004/016272 (2004-02-01), None
Jones, Maitland Organic Chemistry Norton: New York, 1997, p. 84-99.
Dorwald F. A. Side Reactions in Organic Synthesis, 2005, Wiley: VCH, Weinheim p. IX of Preface & p. 41.
“Borane-tetrahydrofuran Complex (BTHF)” Product Bulletin BASF, 2002, p. 1-14.
Yardley, John P. et al. “2-Phenyl-2-( 1-hydroxycycloalkyl)ethylamine Derivatives: Synthesis and Antidepressant Activity” Journal of Medicinal Chemistry 1990, 33, 2899-2905.
Kuo et. al. “G-protein coupled receptors: SAR analyses of neurotransmitters and antagonists” Journal of Clinical Pharmacy and Therapeutics 2004, 29, 279-298.
Martin, Yvonne C. et. al. “Do Structurally Similar Molecules Have Similar Biological Activity?” Journal of Medicinal Chemistry 2002, 45, 4350-4358.
P. C. Meltzer et al. Bioorganic and Medicinal Chemistry 2008, 16, 1832-1841.
Chen et. al. “Studies on the SAR and pharmacophore of milnacipran derivatives as monoamine transporter inhibitors” Bioorganic & Medicinal Chemistry Letters 2008, 18 1346-1349.
U.S. Appl. No. 60/557,651, filed Mar. 30, 2004, Kim et al.
U.S. Appl. No. 60/557,831, filed Mar. 30, 2004, Kim et al.
U.S. Appl. No. 60/569,863, filed May 11, 2004, Kim et al.
U.S. Appl. No. 60/569,861, filed May 11, 2004, Vu.
U.S. Appl. No. 10/963,458, filed Oct. 12, 2004, Mahaney et al.
U.S. Appl. No. 10/962,881, filed Oct. 12, 2004, Mahaney.
U.S. Appl. No. 10/963,064, filed Oct. 12, 2004, Trybulski et al.
U.S. Appl. No. 10/963,111, filed Oct. 12, 2004, Trybulski et al.
U.S. Appl. No. 10/962,880, filed Oct. 12, 2004, Trybulski et al.
U.S. Appl. No. 10/962,897, filed Oct. 12, 2004, Deecher et al.
U.S. Appl. No. 10/962,899, filed Oct. 12, 2004, Mahaney et al.
Clinical Trial: “Phase III Randomized Study of Medroxyprogesterone Versus Venlafaxine in Women With Symptomatic Hot Flashes”, www.clinicaltrials.gov sponsored by the National Institutes of Health, Study ID Nos: CDR0000069217; NCCTG-N99C7; NCI-P02-0204, 2003, 6 pages.
Acs, N. et al., “Estrogen improves impaired musculocutaneous vascular adrenergic reactivity in pharmacologically ovariectomized rats: a potential peripheral mechanism for hot flashes?”,Endocrinology, 2001 15: 68-73.
Barlow, D. H., “Venlafaxine for hot flushes,”Lancet, Dec. 16, 2000, 356(9247): 2025-2026.
Barton, D. et al., “Hot Flashes—Aetiology and Management,”Drugs and Aging, 2001, 18(8): 597-606.
Berendsen, H. H. G., “Hot Flushes and serotonin,”Journal of the British Menopause Society, Mar. 2002, 8(1): 30-34.
Berendsen, H. H. G., “Effect of tibolone and raloxifene on the tail temperature of oestrogen-deficient rats,”European Journal of Pharmacology, 2001, 419(1): 47-54.
Berendsen, H. H. G., “The role of serotonin in hot flushes,”Maturitas, 2000, 36(3): 155-164.
Bundgaard, H., “Means to enhance penetration; Prodrugs as a means to improve the delivery of peptide drugs,”Advanced Drug Deliver Reviews, 1992, 8, 1-38.
Bundgaard, H. et al., “Glycolamide Esters as Biolabile Prodrugs of Carboxylic Acid Agents: Synthesis, Stability, Bioconversion, and Physicochemical Properties,”J. of Pharmaceutical Sciences, Apr. 1988, 77(4):285-298.
Casper, R. F. et al., “Neuroendocrinology of menopausal flushes: an hypothesis of flush mechanism,”Clinical Endocrinology, 1985, 22: 293-312.
Fink, G. et al., “Oestrogen and mental state,”Nature, 1996, 383(6598): 306.
Freedman, R. R. et al., “Clonidine raises the sweating threshold in symptomatic but not asymptomatic postmenopausal women,”Fertility&Sterility, 2000, 74(1): 20-3.
Freedman, R. R., “Physiology of hot flashes,”American Journal of Human Biology, 2001, 13: 453-464.
French, N., “α2-Adrenoceptors and I2sites in the mammalian central nervous system,”Pharmacol. Ther., 1995, 68(2):175-208.
Janowsky, D. S. et al., “Desipramine: an overview,”Journal of Clinical Psychiatry, 1984, 45(10 Pt 2): 3-9.
Katovich, M. J. et al., “Mechanisms Mediating the Thermal Response to Morphine Withdrawal in Rats,”Proceedings of the Society for Experimental Biology&Medicine, 1990, 193(2): 129-35.
Katovich, M. J. et al., “Alpha-adrenergic mediation of the tail skin temperature response to naloxone in morphine-dependent rats,”Brain Research, 1987, 426: 55-61.
Krämer et al., In: Murphy et al.,3rdInt'l Symposium on Recent Advances in Urological Cancer Diagnosis and Treatment-Proceedings, Paris, France: SCI: 3-7 1992.
Krogsgaard-Larsen, et al., (ed).Design and Application of Prodrugs, Textbook of Drug Design and Development, Chapter 5, 113-191, 1991.
Kronenberg, F. et al., “Thermoregulatory Physiology of Menopausal Hot Flashes: A Review,”Can. J. Physiol. Pharmacol., 1987, 65:1312-1324.
Loprinzi, C.L. et al., “ Venlafaxine in management of hot flashes in survivors of breast cancer: a randomized controlled trial,”Lancet, Dec. 16, 2000, 356(9247): 2059-2063.
Loprinizi, C. L. et al. “Pilot Evaluation of Venlafaxine Hydrochloride for the Therapy of Hot Flashes in Cancer Survivors,”Journal of Clinical Oncology, Jul. 1998, 16(7): 2377-2381.
Mackinnon et al., “α2-Adrenoceptors: more subtypes but fewer functional differences,”TIPS, 1994, 15: 119-123.
Merchenthaler et al., “The effect of estrogens and antiestrogens in a rat model for hot flush,”Maturitas, 1998, 30(3): 307-316.
Morin, S. M., “Atomoxetine Selectively Induces Fos Expression in the Rat Prefrontal Cortex,” Presented at Society for Neuroscience Annual Meeting (SFN); Nov. 2-7, 2002, Orlando, FL.
Pacholczyk, T. et al., “Expression cloning of a cocaine-and antidepressant-sensitive human noradrenaline transporter,”Nature, 1991, 350(6316): 350-4.
Panek, D.U. et al., “Effect of continuous intraventricular estrogen or catechol estrogen treatment on catecholamine turnov
Gavrin Lori Krim
Jenkins Douglas John
Mahaney Paige Erin
Carango Paul
Desai Rita J
Mazzarese Joseph
O'Dell David K
Wyeth
LandOfFree
Substituted N-heterocycle derivatives and methods of their use does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Substituted N-heterocycle derivatives and methods of their use, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Substituted N-heterocycle derivatives and methods of their use will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4142484